Company news

Marvel Biosciences Corp news in 2024

Marvel Biosciences Corp's news releases, calls and decks from 2024, newest first.

View company

Marvel Biosciences Announces Promising New Data from Rett Syndrome Study and Plans to Discuss Orphan and Rare Disease Status with the FDA

November 26, 2024

Marvel Biosciences Secures $300,000 Grant to Advance Groundbreaking Alzheimer's Research

November 21, 2024

Marvel Biosciences Announces MB204 Outperforms Approved Drug Trofinetide in a Preclinical Model of Rett Syndrome

November 7, 2024

Marvel Biosciences Shares Positive Results of MB204 in the Oprm1 Model of Autism

October 10, 2024

Marvel Announces Its Collaboration with FRAXA to Test MB204 In Pre-Clinical Models of Fragile X Syndrome

August 13, 2024

Marvel Biosciences Announces Stock Option Grants

July 25, 2024

Marvel Announces an Extension to Its Collaboration with The iBraiN Institute to Test MB204 In a Pre-Clinical Model of Rett Syndrome

July 24, 2024

Marvel Biosciences Closes Private Placement

July 19, 2024

Marvel Highlights New Published Research of Its SAB Member Professor David Blum

July 9, 2024

Marvel Biosciences Announces Private Placement Update

June 21, 2024

Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204

March 25, 2024

Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204

March 12, 2024

Marvel Biosciences Announces Testing MB-204 on Autism by French University

February 20, 2024

Marvel Biosciences Announces Closing of Non-Brokered Private Placement

January 19, 2024

Marvel Biosciences to Collaborate with Tau Expert Dr. Emmanuel Planel

January 8, 2024

Decks in 2024